Suchergebnisse - "Gupta, Neeraj"

PubPharm (9)

1

Clinical Pharmacology of Ixazomib : The First Oral Proteasome Inhibitor

enthalten in: Clinical pharmacokinetics | 2019

von Gupta, N. | Hanley, M. | Xia, C. | +3

2

Oral ixazomib maintenance following autologous stem cell transplantation (TOURMALINE-MM3) : a double-blind, randomised, placebo-controlled phase 3 trial

enthalten in: Lancet (London, England) | 2019

von Dimopoulos, M. | Gay, F. | Schjesvold, F. | +124

CommentIn: Lancet. 2019 Jan 19;393(10168):204-205. - PMID 30545778

3

Biotransformation of [14C]-ixazomib in patients with advanced solid tumors : characterization of metabolite profiles in plasma, urine, and feces

enthalten in: Cancer chemotherapy and pharmacology | 2018

von Pusalkar, S. | Plesescu, M. | Gupta, N. | +6

4

Effects of Strong CYP3A Inhibition and Induction on the Pharmacokinetics of Ixazomib, an Oral Proteasome Inhibitor : Results of Drug-Drug Interaction Studies in Patients With Advanced Solid Tumors or Lymphoma and a Physiologically Based Pharmacokinetic Analysis

enthalten in: Journal of clinical pharmacology | 2018

von Gupta, N. | Hanley, M. | Venkatakrishnan, K. | +13

5

A Phase 1 Study to Assess the Relative Bioavailability of Two Capsule Formulations of Ixazomib, an Oral Proteasome Inhibitor, in Patients With Advanced Solid Tumors or Lymphoma

enthalten in: Journal of clinical pharmacology | 2018

von Hanley, M. | Gupta, N. | Venkatakrishnan, K. | +6

6

Dose and Schedule Selection of the Oral Proteasome Inhibitor Ixazomib in Relapsed/Refractory Multiple Myeloma : Clinical and Model-Based Analyses

enthalten in: Targeted oncology | 2017

von Gupta, N. | Yang, H. | Hanley, M. | +6

7

Exposure-safety-efficacy analysis of single-agent ixazomib, an oral proteasome inhibitor, in relapsed/refractory multiple myeloma : dose selection for a phase 3 maintenance study

enthalten in: Investigational new drugs | 2016

von Gupta, N. | Labotka, R. | Liu, G. | +2

8

Pharmacokinetics and safety of ixazomib plus lenalidomide-dexamethasone in Asian patients with relapsed/refractory myeloma : a phase 1 study

enthalten in: Journal of hematology & oncology | 2015

von Gupta, N. | Goh, Y. | Min, C. | +10

9

Switching from body surface area-based to fixed dosing for the investigational proteasome inhibitor ixazomib : a population pharmacokinetic analysis

enthalten in: British journal of clinical pharmacology | 2015

von Gupta, N. | Zhao, Y. | Hui, A. | +2

1
[1]